PFE Pfizer, Inc. Common Stock
Tentang Pfizer, Inc. Common Stock Tinjauan perusahaan dari Wikipedia
Pfizer Inc. adalah sebuah perusahaan farmasi asal Amerika. Perusahaan ini merupakan salah satu perusahaan farmasi terbesar di dunia dan menempati peringkat ke-57 dalam daftar Fortune 500 tahun 2018.
Baca selengkapnya
Pfizer Inc. () adalah sebuah perusahaan farmasi asal Amerika. Perusahaan ini merupakan salah satu perusahaan farmasi terbesar di dunia dan menempati peringkat ke-57 dalam daftar Fortune 500 tahun 2018.
Berkantor pusat di New York City, Pfizer mengembangkan dan memproduksi obat dan vaksin untuk berbagai macam disiplin medis, termasuk imunologi, onkologi, kardiologi, endokrinologi, dan neurologi. Produknya meliputi obat blockbuster Lipitor (atorvastatin), yang digunakan untuk menurunkan kolesterol darah LDL; Lyrica (pregabalin) untuk nyeri neuropatik dan fibromialgia; Diflucan (flukonazol), sebuah medikasi antijamur oral; Zithromax (azitromisin), sebuah antibiotik; Viagra (sildenafil) untuk disfungsi erektil; dan Celebrex (juga Celebra, selekoksib), sebuah obat antiinflamasi nonsteroid.
Pada tahun 2016, Pfizer Inc. diperkirakan akan bergabung dengan Allergan untuk membentuk "Pfizer plc", dalam sebuah kesepakatan yang diperkirakan bernilai US$160 miliar. Namun penggabungan tersebut dibatalkan pada bulan April 2016, karena adanya aturan baru dari Departemen Keuangan Amerika Serikat mengenai inversi pajak, sebuah metode penghindaran pajak yang dilakukan dengan cara bergabung dengan perusahaan dari luar Amerika Serikat.
Pada tanggal 19 Desember 2018, Pfizer mengumumkan penggabungan divisi perawatan kesehatan ritel miliknya dengan GlaxoSmithKline, di mana GlaxoSmithKline akan memegang 68% saham perusahaan tersebut.
Pfizer merupakan salah satu komponen dari Dow Jones Industrial Average mulai tahun 2004 hingga 2020, setelah perusahaan ini digantikan oleh Amgen. Penggantian tersebut mulai berlaku pada tanggal 31 Agustus 2020.
Sejarah
1849–2000
Pada tahun 1849, Pfizer didirikan di New York City oleh seorang Jerman-Amerika, Charles Pfizer (sebenarnya bernama Karl Pfizer) bersama sepupunya, Charles F. Erhart dari Ludwigsburg, Jerman. Perusahaan inipun diberi nama Charles Pfizer and Company, dengan fasilitas produksi di Bartlett Street, Williamsburg, Brooklyn. Perusahaan ini awalnya memproduksi sebuah antiparasit bernama santonin. Produk tersebut pun sangat laku, walaupun kemudian produk asam sitrat lah yang membuat Pfizer dapat tumbuh pesat pada dekade 1880-an. Perusahaan ini pun terus membeli properti untuk mengembangkan laboratorium dan pabriknya. Kantor pusat Pfizer awalnya berlokasi di Maiden Lane no. 81, Manhattan. Pada tahun 1906, penjualan tahunan Pfizer telah mencapai $3 juta.
Perang Dunia I menyebabkan kurangnya pasokan kalsium sitrat, yang biasanya Pfizer impor dari Italia untuk memproduksi asam sitrat, sehingga perusahaan ini pun mulai mencari pasokan alternatif. Ahli kimia Pfizer kemudian mengetahui bahwa sebuah jamur dapat memfermentasi gula menjadi asam sitrat, sehingga Pfizer mulai mengkomersialkan produksi asam sitrat dengan metode tersebut pada tahun 1919. Sebagai hasilnya, perusahaan inipun mengembangkan keahlian di bidang teknologi fermentasi. Keahlian tersebut lalu diaplikasikan untuk memproduksi antibiotik penisilin secara masal selama Perang Dunia II, karena adanya kebutuhan untuk merawat tentara Sekutu yang terluka. Sebagian besar penisilin yang dibawa oleh pasukan di D-Day diproduksi oleh Pfizer.
Penisilin menjadi sangat murah pada dekade 1940-an, sehingga Pfizer mulai mencari antibiotik lain yang dapat menghasilkan lebih banyak laba. Pfizer lalu menemukan Terramisin (oksitetrasiklin) pada tahun 1950, dan penemuan tersebut pun mengubah perusahaan ini dari sebuah produsen bahan kimia murni menjadi sebuah perusahaan farmasi berbasis riset. Pfizer mengembangkan sebuah program penemuan obat yang fokus pada sintesis vitro untuk mengembangkan risetnya di bidang teknologi fermentasi. Perusahaan ini juga mendirikan divisi kesehatan hewan pada tahun 1959, lengkap dengan sebuah peternakan dan fasilitas riset seluas 700-ekar (2,8 km2) di Terre Haute, Indiana.
Pada dekade 1950-an, Pfizer telah mendirikan kantor di Belgia, Brazil, Kanada, Kuba, Meksiko, Panama, Puerto Riko, dan Britania Raya. Pada tahun 1960, perusahaan ini memindahkan laboratorium risetnya dari New York City ke Groton, Connecticut. Pada tahun 1980, Pfizer meluncurkan Feldene (piroksikam), sebuah obat resep anti-inflamasi, yang kemudian menjadi produk pertama Pfizer yang penjualannya dapat mencapai satu miliar dolar. Selama dekade 1980-an dan 1990-an, pertumbuhan Pfizer didukung oleh penemuan dan pemasaran Zoloft, Lipitor, Norvasc, Zithromax, Aricept, Diflucan, dan Viagra.
2000–2010
Pada dekade ini, Pfizer tumbuh melalui penggabungan, termasuk dengan Warner–Lambert (2000), Pharmacia (2003), dan Wyeth (2009).
Pada tahun 2003, perusahaan ini mengakuisisi Esperion Therapeutics dengan harga $1,3 miliar (kemudian dijual pada tahun 2008), melindungi Lipitor dari ETC-216. Pada tahun 2004, Pfizer mengumumkan bahwa mereka akan mengakuisisi Meridica dengan harga $125 juta. Pada tahun 2005, perusahaan ini mengakuisisi Vicuron Pharmaceuticals dengan harga $1,9 miliar, Idun dengan harga hampir $300 juta, dan Angiosyn dengan harga $527 juta.
Pengembangan torsetrapib, sebuah obat untuk meningkatkan produksi HDL, atau "kolesterol baik", guna mengurangi LDL yang diduga menyebabkan penyakit hati, ditunda pada bulan Desember 2006. Selama uji klinis fase III yang melibatkan 15.000 pasien, lebih banyak kematian terjadi pada kelompok yang mengkonsumsi obat lebih banyak dari yang diharapkan, dan 60% peningkatan kematian pada pasien yang mengkonsumsi kombinasi torsetrapib dan Lipitor, daripada jika mengkonsumsi Lipitor saja. Pfizer merugi hampir $1 miliar dalam pengembangan obat gagal tersebut dan nilai pasar Pfizer pun ikut turun. Pada tahun yang sama, perusahaan ini juga mengumumkan bahwa mereka akan mengakuisisi PowerMed dan Rivax.
Pada bulan September 2009, Pfizer divonis bersalah atas pemasaran obat artritis Bextra secara ilegal, karena belum disetujui oleh Food and Drug Administration. Pfizer kemudian setuju untuk membayar uang damai sebesar $2,3 miliar.
BusinessWeek pada bulan Juli 2010 memberitakan bahwa Pfizer berupaya melawan produsen obat resep imitasi melalui tuntutan sipil, bukannya tuntutan kriminal. Pfizer pun mempekerjakan ahli narkotika dan ahli pabean dari seluruh dunia untuk melacak dan merangkai bukti-bukti yang dapat digunakan untuk menuntut produsen tersebut atas pelanggaran merek dagang. Sejak tahun 2007, Pfizer telah menghabiskan $3,3 juta untuk melakukan investigasi dan berhasil mendapat sekitar $5.1 juta, dengan potensi $5 juta lainnya masih dalam proses persidangan.
Pada tanggal 6 Mei 2013, Pfizer memberitahu Associated Press bahwa mereka akan mulai menjual Viagra langsung ke pasien melalui situs webnya.
2000: Akuisisi Warner–Lambert
Pfizer mengakuisisi Warner–Lambert pada tahun 2000 dengan harga $111,8 miliar, sehingga pada saat itu, menghasilkan perusahaan farmasi terbesar kedua di dunia. Warner–Lambert didirikan sebagai sebuah apotek di Philadelphia pada tahun 1856 oleh William R. Warner. Proses pelapisan tablet yang diciptakan oleh Warner membuatnya dapat masuk ke dalam Smithsonian Institution. Sementara Parke–Davis didirikan di Detroit pada tahun 1866 oleh Hervey Parke dan George Davis. Warner–Lambert mengambil alih Parke–Davis pada tahun 1976, dan mengakuisisi Wilkinson Sword pada tahun 1993, serta Agouron Pharmaceuticals pada tahun 1999.
2003: Akuisisi Pharmacia
Pada tahun 2003, Pfizer bergabung dengan Pharmacia. Penggabungan tersebut salah satunya didorong oleh keinginan untuk mendapatkan hak penuh atas Celebrex (selekoksib), sebuah inhibitor selektif COX-2 yang sebelumnya dipasarkan secara bersama-sama oleh Searle (diakuisisi oleh Pharmacia) dan Pfizer. Pada tahun-tahun berikutnya, Pfizer mengadakan restrukturisasi besar-besaran, termasuk menutup fasilitas dan mengurangi jumlah pekerjanya di Terre Haute, Indiana; Holland, Michigan; Groton, Connecticut; Brooklyn, New York; Sandwich, Amerika Serikat; dan Puerto Riko.
Pharmacia dibentuk melalui serangkaian penggabungan dan akuisisi. Para pendahulunya antara lain Searle, Upjohn, dan SUGEN.
Pada bulan April 1888, Searle didirikan di Omaha, Nebraska oleh Gideon Daniel Searle. Pada tahun 1908, Searle resmi didaftarkan sebagai sebuah badan hukum di Chicago, Illinois. Pada tahun 1941, Searle mendirikan kantor pusatnya di Skokie, Illinois. Searle kemudian diakuisisi oleh Monsanto Company pada tahun 1985.
The Upjohn Company adalah sebuah perusahaan farmasi yang didirikan pada tahun 1886 di Kalamazoo, Michigan, oleh Dr. William E. Upjohn. Perusahaan ini awalnya didirikan untuk memproduksi pil gembur, yang dirancang untuk dapat dicerna dengan mudah. Greenstone didirikan pada tahun 1993 oleh Upjohn sebagai divisi obat generik. Pada tahun 1995, Upjohn bergabung dengan Pharmacia, untuk membentuk Pharmacia & Upjohn. Pharmacia dibentuk pada bulan April 2000 melalui penggabungan Pharmacia & Upjohn dengan Monsanto Company dan G.D. Searle. Perusahaan hasil penggabungan tersebut pun berkantor pusat di Peapack, New Jersey. Divisi pertanian kemudian dipisah dari Pharmacia dengan nama Monsanto, sebagai bagian dari persiapan sebelum Pharmacia resmi diakuisisi oleh Pfizer.
Perubahan
GSK dan Pfizer menggabungkan bisnis produk perawatan kesehatan konsumen pada tahun 2019. GSK dan Pfizer memisahkan bisnis produk perawatan kesehatan konsumen membentuk Haleon pada tanggal 18 Juli 2022. Haleon saat ini produk perawatan kesehatan konsumen.
GSK dan Pfizer saat ini produk vaksin dan obat resep dokter.
Referensi
Pranala luar
Situs web resmi
Data bisnis Pfizer:
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
PFE Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
PFE Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
| Tanggal ex-dividen | Jumlah |
|---|---|
| 24 Juli 2026 | $0,4300 |
| 8 Mei 2026 | $0,4300 |
| 23 Jan. 2026 | $0,4300 |
| 7 Nov. 2025 | $0,4300 |
| 25 Juli 2025 | $0,4300 |
| 9 Mei 2025 | $0,4300 |
| 24 Jan. 2025 | $0,4300 |
| 8 Nov. 2024 | $0,4200 |
| 26 Juli 2024 | $0,4200 |
| 9 Mei 2024 | $0,4200 |
| 25 Jan. 2024 | $0,4200 |
| 9 Nov. 2023 | $0,4100 |
| 27 Juli 2023 | $0,4100 |
| 11 Mei 2023 | $0,4100 |
| 26 Jan. 2023 | $0,4100 |
| 3 Nov. 2022 | $0,4000 |
| 28 Juli 2022 | $0,4000 |
| 12 Mei 2022 | $0,4000 |
| 27 Jan. 2022 | $0,4000 |
| 4 Nov. 2021 | $0,3900 |
PFE Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
- Beli Kuat 6 16,7%
- Beli 8 22,2%
- Tahan 20 55,6%
- Jual 1 2,8%
- Jual Kuat 1 2,8%
Target Harga 12 Bulan
26 analis · 2026-08-17Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $0.77 | $0.69 | 0.08% |
| 31 Maret 2026 | $0.75 | $0.72 | 0.03% |
| 31 Des. 2025 | $0.66 | $0.58 | 0.08% |
| 30 Sep. 2025 | $0.87 | $0.64 | 0.23% |
| 30 Juni 2025 | $0.78 | $0.59 | 0.19% |
| 31 Maret 2025 | $0.92 | $0.67 | 0.25% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B | $41.65B | $40.91B | $40.83B | · | $52.82B | $48.85B | |
| Cost of Revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B | $8.99B | · | $12.32B | $9.65B | |
| SG&A Expense | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | $11.60B | $12.73B | $12.61B | · | $14.84B | $14.81B | |
| Interest Expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B | $1.57B | $1.32B | · | $1.19B | $1.20B | |
| Interest Income | $603M | $545M | $1.62B | $251M | $36M | $73M | $225M | $333M | · | $470M | $471M | |
| Other Non-op | $-6.72B | $-4.39B | $-222M | $-1.06B | $4.88B | $-1.21B | $-3.50B | $-2.08B | · | $-3.79B | $-2.86B | |
| Pretax Income | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.04B | $11.32B | $3.59B | · | $8.35B | $8.96B | |
| Income Tax | $-266M | $-28M | $-1.11B | $3.33B | $1.85B | $370M | $583M | $-266M | · | $1.12B | $1.99B | |
| Net Income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | · | $7.21B | $6.96B | |
| EPS (Basic) | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 | $1.65 | $2.88 | $1.90 | · | $1.18 | $1.13 | |
| EPS (Diluted) | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 | · | $1.17 | $1.11 | |
| Shares (Basic) | 5,683,000,000 | 5,664,000,000 | 5,643,000,000 | 5,608,000,000 | 5,601,000,000 | 5,555,000,000 | 5,569,000,000 | 5,872,000,000 | · | 6,089,000,000 | 6,176,000,000 | |
| Shares (Diluted) | 5,713,000,000 | 5,700,000,000 | 5,709,000,000 | 5,733,000,000 | 5,708,000,000 | 5,632,000,000 | 5,675,000,000 | 5,977,000,000 | · | 6,159,000,000 | 6,257,000,000 | |
| EBITDA | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B | · | $6.01B | $6.38B | · | $5.76B | $5.16B |
Neraca 29
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.14B | $1.04B | $2.85B | $416M | $1.94B | $1.79B | $1.12B | $1.14B | · | $2.60B | $3.64B | |
| Short-term Investments | · | · | · | · | · | $10.44B | $8.53B | $17.69B | · | $15.26B | $19.65B | |
| Receivables | $11.87B | $11.46B | $11.57B | $10.95B | $11.48B | $7.91B | $6.77B | $8.03B | $8.23B | $8.22B | $8.18B | |
| Inventory | $10.65B | $10.85B | $10.19B | $8.98B | $9.06B | $8.02B | $7.07B | $7.51B | $7.57B | $6.78B | $7.51B | |
| Other Current Assets | $2.81B | $4.25B | $4.91B | $5.02B | $3.82B | $3.65B | $2.36B | $2.46B | · | $2.25B | $2.15B | |
| Current Assets | $42.90B | $50.36B | $43.33B | $51.26B | $59.69B | $35.07B | $32.80B | $49.93B | · | $38.95B | $43.80B | |
| PP&E (Net) | $19.32B | $18.39B | $18.94B | $16.27B | $14.88B | $13.74B | $12.97B | $13.38B | · | $13.32B | $13.77B | |
| PP&E (Gross) | $36.70B | $34.88B | $34.98B | $31.45B | $29.95B | $28.41B | $27.96B | $29.98B | · | $28.12B | $27.27B | |
| Accum. Depreciation | $17.39B | $16.48B | $16.05B | $15.17B | $15.07B | $14.66B | $14.99B | $16.59B | · | $14.81B | $13.50B | |
| Goodwill | $71.26B | $68.53B | $67.78B | $51.38B | $49.21B | $49.56B | $48.18B | $42.93B | · | $54.45B | $48.24B | |
| Intangibles | $53.73B | $55.41B | $64.90B | $43.37B | $25.15B | $28.34B | $33.94B | $35.21B | · | $52.65B | $40.36B | |
| Other Non-current Assets | $9.63B | $9.82B | $12.47B | $13.16B | $7.68B | $4.88B | $4.20B | $2.80B | $3.02B | $3.32B | $3.42B | |
| Total Assets | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B | $154.23B | $167.59B | $159.42B | · | $171.62B | $167.38B | |
| Accounts Payable | $5.24B | $5.63B | $6.71B | $6.81B | $5.58B | $4.28B | $3.89B | $4.67B | · | $4.54B | $3.62B | |
| Short-term Debt | $0 | $2.45B | $7.96B | $0 | $0 | $556M | $13.91B | $3.10B | · | $5.80B | · | |
| Current Liabilities | $36.98B | $42.99B | $47.79B | $42.14B | $42.67B | $25.92B | $37.30B | $31.86B | · | $31.11B | $29.40B | |
| Capital Leases | $2.29B | $2.29B | $2.63B | $2.60B | $2.51B | $1.11B | $1.03B | · | · | · | · | |
| Deferred Tax | $2.40B | $2.12B | $640M | $1.02B | $349M | $4.06B | $5.65B | $3.70B | $3.99B | $30.75B | $26.88B | |
| Other Non-current Liabilities | $14.72B | $14.15B | $16.54B | $13.18B | $9.74B | $6.67B | $6.89B | $5.85B | $5.69B | $6.34B | $5.26B | |
| Total Liabilities | $121.39B | $124.90B | $137.21B | $101.29B | $104.01B | $90.76B | $104.15B | $95.66B | · | $111.78B | $102.38B | |
| Long-term Debt | $64.64B | $61.15B | $63.79B | $35.44B | $37.83B | $4.00B | $37.42B | $37.69B | · | $31.40B | $28.82B | |
| Total Debt | $64.64B | $63.60B | $71.76B | $35.44B | $37.83B | $39.69B | $51.33B | $40.78B | · | $35.62B | $32.54B | |
| Common Stock | $481M | $480M | $478M | $476M | $473M | $470M | $468M | $467M | · | $461M | $459M | |
| Paid-in Capital | $94.47B | $93.60B | $92.63B | $91.80B | $90.59B | $88.67B | $87.43B | $86.25B | · | $82.69B | $81.02B | |
| Retained Earnings | $114.61B | $116.72B | $118.35B | $125.66B | $103.39B | $90.39B | $97.67B | $89.55B | $86.47B | $71.77B | $71.99B | |
| Treasury Stock | $115.02B | $114.76B | $114.49B | $113.97B | $111.36B | $110.99B | $110.80B | $101.61B | · | $84.36B | $79.25B | |
| AOCI | $-8.07B | $-7.84B | $-7.96B | $-8.30B | $-5.90B | $-5.31B | $-11.64B | $-11.28B | $-10.23B | $-11.04B | $-9.52B | |
| Stockholders' Equity | $86.48B | $88.20B | $89.01B | $95.66B | $77.20B | $63.24B | $63.14B | $63.41B | · | $59.54B | $64.72B | |
| Liabilities + Equity | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B | $154.23B | $167.59B | $159.42B | · | $171.62B | $167.38B |
Arus Kas 18
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B | $4.68B | $5.75B | $6.38B | · | $5.76B | $5.16B | |
| Stock-based Comp | $799M | $877M | $525M | $872M | $1.18B | $755M | $687M | $923M | · | $691M | $669M | |
| Deferred Tax | $-2.13B | $-2.10B | $-3.44B | $-3.76B | $-4.29B | $-1.57B | $561M | $-2.20B | · | $-700M | $-20M | |
| Amort. of Intangibles | · | $5.30B | $4.70B | $3.60B | $3.70B | $3.40B | $4.50B | · | · | · | $3.80B | |
| Restructuring | $1.09B | $1.99B | $1.97B | $882M | $741M | $535M | $227M | $796M | · | $1.05B | $811M | |
| Other Non-cash | $-1.32B | $-1.07B | $3.21B | $-4.28B | $8.52B | · | $-11.03B | $-454M | · | $2.94B | $1.75B | |
| Operating Cash Flow | $11.70B | $12.74B | $8.70B | $29.27B | $32.58B | $14.40B | $12.59B | $15.83B | · | $16.19B | $14.69B | |
| CapEx | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B | $2.23B | $2.05B | $1.98B | · | $1.82B | $1.40B | |
| Investing Cash Flow | $-1.35B | $2.65B | $-32.28B | $-15.78B | $-22.55B | $-4.27B | $-3.94B | $4.53B | · | $-7.79B | $-2.98B | |
| Debt Issued | $9.68B | $0 | $30.83B | $0 | $997M | $5.22B | $4.94B | $4.97B | · | $10.98B | $0 | |
| Net Debt Issued | $2.92B | $-2.25B | $28.26B | $-3.30B | $-1.01B | $1.22B | $-1.86B | $1.41B | · | $3.29B | $-3.00B | |
| Stock Repurchased | · | $0 | $0 | $2.00B | $0 | $0 | $8.87B | $12.20B | · | $5.00B | $6.16B | |
| Net Stock Activity | · | $0 | $0 | $-2.00B | $0 | $0 | $-8.87B | $-12.20B | · | $-5.00B | $-6.16B | |
| Financing Cash Flow | $-10.30B | $-17.14B | $26.07B | $-14.83B | $-9.82B | $-9.65B | $-8.48B | $-20.44B | · | $-9.23B | $-10.41B | |
| Net Change in Cash | $91M | $-1.81B | $2.45B | $-1.51B | $159M | $475M | $125M | $-205M | · | $-1.04B | $298M | |
| Taxes Paid | $4.69B | $3.60B | $3.15B | $7.87B | $7.43B | $3.15B | $3.66B | $3.65B | · | $2.52B | $2.38B | |
| Free Cash Flow | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B | $12.15B | $10.41B | $13.79B | · | $14.08B | $13.12B | |
| Levered FCF | $6.31B | $6.73B | $256M | $24.91B | $28.68B | $10.79B | $8.96B | $12.55B | · | $13.05B | $12.18B |
Profitabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 12.4% | 12.6% | 3.6% | 31.3% | 27.0% | 22.9% | 31.4% | 20.8% | · | 13.7% | 14.2% | |
| Pretax Margin | 12.0% | 12.6% | 1.8% | 34.6% | 29.9% | 17.9% | 34.2% | 22.1% | · | 15.8% | 18.4% | |
| EBITDA Margin | 10.5% | 11.0% | 10.8% | 5.1% | 6.4% | · | 11.6% | 11.9% | · | 10.9% | 10.6% | |
| ROA | 3.7% | 3.6% | 1.0% | 16.6% | 13.1% | 6.0% | 10.0% | 6.7% | · | 4.3% | 4.2% | |
| ROE | 8.9% | 9.1% | 2.3% | 36.3% | 31.3% | 15.2% | 25.7% | 16.6% | · | 11.6% | 10.2% |
Likuiditas & Solvabilitas 4
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | 1.2 | 0.9 | 1.2 | 1.4 | 1.4 | 0.9 | 1.6 | · | 1.3 | 1.5 | |
| Quick Ratio | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.8 | · | 0.8 | 1.1 | |
| Debt / Equity | 0.7 | 0.7 | 0.8 | 0.4 | 0.5 | 0.6 | 0.8 | 0.6 | · | 0.6 | 0.5 | |
| LT Debt / Equity | 0.7 | 0.7 | 0.7 | 0.3 | 0.5 | 0.6 | 0.6 | 0.5 | · | 0.5 | 0.4 |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.3 | 0.5 | 0.5 | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | |
| Inventory Turnover | 1.5 | 1.7 | 2.6 | 3.8 | 3.6 | 1.2 | 1.3 | 1.5 | · | 1.7 | 1.5 | |
| Receivables Turnover | 5.4 | 5.5 | 5.3 | 8.9 | 8.4 | 5.7 | 6.2 | 6.6 | · | 6.4 | 5.9 |
Tingkat Pertumbuhan 9
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -1.7% | 6.8% | -41.1% | 24.5% | 95.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -14.8% | -7.8% | 12.7% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.5% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -3.5% | 281.1% | -93.2% | 42.1% | 136.2% | · | · | · | · | · | · | |
| EPS CAGR 3Y | -37.1% | -28.4% | -39.0% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.6% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -3.2% | 279.0% | -93.2% | 42.7% | 140.0% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -37.2% | -28.5% | -38.6% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -3.2% | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 4
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B | $41.65B | $40.91B | $40.83B | · | $52.82B | $48.85B | |
| Net Income TTM | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | · | $7.21B | $6.96B | |
| P/E | 18.3 | 18.8 | 77.8 | 9.4 | 15.3 | 22.6 | 13.2 | 22.1 | · | 26.3 | 27.6 | |
| Earnings Yield | 5.5% | 5.3% | 1.3% | 10.7% | 6.5% | 4.4% | 7.6% | 4.5% | · | 3.8% | 3.6% |
Laporan Laba Rugi 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.71B | $17.76B | $17.70B | $13.28B | $14.88B | $14.57B | $13.01B | $18.49B | $25.14B | |
| Cost of Revenue | $4.09B | $3.55B | $5.27B | $4.17B | $3.78B | $2.85B | $5.91B | $5.26B | $3.30B | $3.38B | $7.56B | $3.24B | $4.89B | $9.65B | |
| SG&A Expense | $3.41B | $2.96B | $4.16B | $3.19B | $3.42B | $3.03B | $4.27B | $3.24B | $3.72B | $3.50B | $4.58B | $3.50B | $3.42B | $4.64B | |
| Interest Expense | $667M | $668M | $711M | $652M | $654M | $654M | $740M | $783M | $778M | $790M | $688M | $508M | $318M | $313M | |
| Interest Income | $113M | $115M | $166M | $138M | $156M | $143M | $170M | $116M | $130M | $129M | $609M | $316M | $177M | $137M | |
| Other Non-op | $-3.72B | $-861M | $-4.51B | $-517M | $-739M | $-953M | $-2.36B | $-243M | $-1.11B | $-680M | $159M | $75M | $-275M | $1M | |
| Pretax Income | $-653M | $3.17B | $-1.64B | $3.33B | $3.04B | $2.79B | $-10M | $4.71B | $-103M | $3.42B | $-4.13B | $2.27B | $6.27B | $5.23B | |
| Income Tax | $-407M | $461M | $-2M | $-216M | $141M | $-189M | $-421M | $234M | $-134M | $293M | $-795M | $-71M | $715M | $230M | |
| Net Income | $-248M | $2.69B | $-1.65B | $3.54B | $2.91B | $2.97B | $410M | $4.46B | $41M | $3.12B | $-3.37B | $2.33B | $5.54B | $4.99B | |
| EPS (Basic) | $-0.04 | $0.47 | $-0.28 | $0.62 | $0.51 | $0.52 | $0.07 | $0.79 | $0.01 | $0.55 | $-0.59 | $0.41 | $0.98 | $0.88 | |
| EPS (Diluted) | $-0.04 | $0.47 | $-0.29 | $0.62 | $0.51 | $0.52 | $0.07 | $0.78 | $0.01 | $0.55 | $-0.59 | $0.41 | $0.97 | $0.87 | |
| Shares (Basic) | 5,699,000,000 | 5,691,000,000 | -11,362,000,000 | 5,685,000,000 | 5,685,000,000 | 5,675,000,000 | -11,326,000,000 | 5,667,000,000 | 5,666,000,000 | 5,657,000,000 | 1,000,000 | 5,646,000,000 | 5,634,000,000 | 2,000,000 | |
| Shares (Diluted) | 5,699,000,000 | 5,731,000,000 | -11,417,000,000 | 5,714,000,000 | 5,706,000,000 | 5,710,000,000 | -11,398,000,000 | 5,705,000,000 | 5,696,000,000 | 5,697,000,000 | -5,000,000 | 5,713,000,000 | 5,727,000,000 | 4,000,000 | |
| EBITDA | $1.62B | $1.61B | · | $1.66B | $1.62B | $1.62B | · | · | · | $1.74B | · | · | · | · |
Neraca 28
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $976M | $1.70B | $1.14B | $1.34B | $1.64B | $1.43B | $1.04B | $1.09B | $1.05B | $719M | · | $2.63B | $2.17B | · | |
| Receivables | $12.49B | $12.59B | $11.87B | $14.26B | $12.08B | $11.85B | $11.46B | $14.45B | $11.39B | $10.99B | · | $10.23B | $12.30B | · | |
| Inventory | $9.95B | $10.67B | $10.65B | $11.47B | $11.67B | $10.85B | $10.85B | $11.72B | $11.45B | $10.89B | · | $10.31B | $9.54B | · | |
| Other Current Assets | $3.52B | $2.91B | $2.81B | $2.36B | $2.69B | $2.95B | $4.25B | $3.85B | $4.19B | $4.37B | · | $4.83B | $5.12B | · | |
| Current Assets | $41.36B | $42.82B | $42.90B | $46.92B | $43.70B | $45.86B | $50.36B | $43.22B | $37.83B | $42.41B | · | $73.35B | $50.08B | · | |
| PP&E (Net) | $19.03B | $19.40B | $19.32B | $18.88B | $18.78B | $18.35B | $18.39B | $18.54B | $18.96B | $18.80B | · | $17.49B | $17.05B | · | |
| PP&E (Gross) | · | · | $36.70B | · | · | · | $34.88B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $18.10B | $17.80B | $17.39B | $17.50B | $17.27B | $16.84B | $16.48B | $16.68B | $16.57B | $16.36B | · | $15.55B | $15.51B | · | |
| Goodwill | $71.42B | $71.41B | $71.26B | $69.10B | $69.00B | $68.44B | $68.53B | $68.57B | $68.44B | $69.30B | $67.78B | $51.57B | $51.48B | $51.38B | |
| Intangibles | $47.05B | $52.56B | $53.73B | $51.32B | $52.70B | $53.98B | $55.41B | $59.99B | $61.24B | $62.83B | · | $41.41B | $42.00B | · | |
| Other Non-current Assets | $9.94B | $9.83B | $9.63B | $9.32B | $9.46B | $9.85B | $9.82B | $10.49B | $10.71B | $11.20B | · | $13.03B | $12.96B | · | |
| Total Assets | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B | $216.19B | $221.09B | · | $220.17B | $195.62B | · | |
| Accounts Payable | $4.58B | $4.51B | $5.24B | $5.02B | $5.17B | $5.24B | $5.63B | $5.31B | $5.11B | $5.59B | · | $6.08B | $6.12B | · | |
| Short-term Debt | · | · | $0 | $0 | $0 | $155M | $2.45B | $5.84B | $7.96B | $6.93B | · | · | · | · | |
| Current Liabilities | $32.65B | $34.35B | $36.98B | $36.60B | $37.73B | $36.45B | $42.99B | $43.21B | $43.82B | $40.50B | · | $34.65B | $36.56B | · | |
| Capital Leases | · | · | $2.29B | · | · | · | $2.29B | · | · | · | · | · | · | · | |
| Deferred Tax | $1.96B | $2.41B | $2.40B | $2.47B | $2.48B | $2.26B | $2.12B | $2.16B | $2.23B | $931M | · | $1.23B | $1.07B | · | |
| Other Non-current Liabilities | $14.78B | $14.20B | $14.72B | $13.61B | $13.93B | $13.30B | $14.15B | $15.57B | $16.09B | $15.12B | · | $13.40B | $13.01B | · | |
| Total Liabilities | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B | $117.39B | $124.90B | $126.92B | $128.22B | $128.54B | · | $120.88B | $94.38B | · | |
| Long-term Debt | $63.10B | $64.43B | $64.64B | $61.66B | $61.75B | $61.39B | $61.15B | $61.75B | $61.25B | $62.31B | · | $64.92B | $35.27B | · | |
| Total Debt | $63.10B | $64.43B | · | $61.66B | $61.75B | $61.54B | · | $67.59B | $69.22B | $69.24B | · | · | · | · | |
| Common Stock | $482M | $482M | $481M | $481M | $481M | $481M | $480M | $480M | $480M | $480M | · | $478M | $478M | · | |
| Paid-in Capital | $95.03B | $94.77B | $94.47B | $94.25B | $94.05B | $93.86B | $93.60B | $93.48B | $93.20B | $93.00B | · | $92.33B | $92.15B | · | |
| Retained Earnings | $112.09B | $117.24B | $114.61B | $121.15B | $117.61B | $119.59B | $116.72B | $121.06B | $116.60B | $121.32B | · | $128.80B | $131.10B | · | |
| Treasury Stock | $115.19B | $115.19B | $115.02B | $115.01B | $115.01B | $115.01B | $114.76B | $114.76B | $114.76B | $114.75B | · | $114.48B | $114.47B | · | |
| AOCI | $-7.22B | $-7.20B | $-8.07B | $-8.07B | $-8.44B | $-8.58B | $-7.84B | $-7.97B | $-7.82B | $-7.76B | · | $-8.10B | $-8.29B | · | |
| Stockholders' Equity | $85.19B | $90.10B | $86.48B | $92.80B | $88.69B | $90.34B | $88.20B | $92.29B | $87.70B | $92.28B | · | $99.02B | $100.97B | · | |
| Liabilities + Equity | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B | $216.19B | $221.09B | · | $220.17B | $195.62B | · |
Arus Kas 18
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.62B | $1.61B | $1.69B | $1.66B | $1.62B | $1.62B | $1.79B | $1.75B | $1.73B | $1.74B | $1.67B | · | $1.49B | $1.52B | |
| Stock-based Comp | $249M | $272M | $225M | $201M | $203M | $170M | $177M | $274M | $206M | $220M | $121M | · | $105M | $364M | |
| Deferred Tax | $-1.32B | $-12M | $-433M | $-765M | $-272M | $-663M | $-396M | $-482M | $-783M | $-441M | $-1.86B | · | $-598M | $-365M | |
| Amort. of Intangibles | · | · | · | $1.20B | $1.20B | $1.20B | · | $1.30B | $1.30B | $1.30B | · | · | · | · | |
| Restructuring | $419M | $49M | $308M | $237M | $-74M | $621M | $656M | $217M | $1.10B | $10M | $1.80B | $138M | $-44M | $514M | |
| Other Non-cash | · | $-3.68B | · | · | · | $-3.68B | · | · | · | $-6.88B | · | · | · | · | |
| Operating Cash Flow | $835M | $2.62B | $5.35B | $4.60B | $-582M | $2.33B | $6.72B | $6.71B | $-1.78B | $1.09B | $5.24B | · | $1.21B | $8.58B | |
| CapEx | $533M | $436M | $845M | $602M | $618M | $564M | $917M | $651M | $637M | $704M | $1.04B | · | $1.14B | $1.00B | |
| Investing Cash Flow | $2.11B | $785M | $-6.15B | $-2.43B | $3.95B | $3.27B | $-1.62B | $-2.06B | $4.60B | $1.73B | $-11.00B | · | $3.31B | $-4.41B | |
| Debt Issued | · | · | $5.99B | $0 | · | · | $0 | $0 | · | · | $0 | · | · | $0 | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $-1.25B | · | · | $-269M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-3.66B | $-2.86B | $596M | $-2.48B | $-3.20B | $-5.23B | $-5.11B | $-4.64B | $-2.46B | $-4.93B | $5.44B | · | $-2.77B | $-5.01B | |
| Net Change in Cash | $-727M | $563M | $-196M | $-301M | $213M | $375M | $-45M | $29M | $343M | $-2.14B | $-316M | · | $1.75B | $-869M | |
| Taxes Paid | $3.47B | $72M | $1.02B | $178M | $3.34B | $152M | $433M | $486M | $2.50B | $184M | $240M | · | $329M | $2.95B | |
| Free Cash Flow | · | $2.18B | · | · | · | $1.77B | · | · | · | $386M | · | · | $73M | · | |
| Levered FCF | · | $1.61B | · | · | · | $1.07B | · | · | · | $-336M | · | · | $-209M | · |
Profitabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -1.7% | 18.6% | · | 21.3% | 19.9% | 21.6% | · | 25.2% | 0.31% | 20.9% | · | 18.3% | 30.3% | · | |
| Pretax Margin | -4.3% | 21.9% | · | 20.0% | 20.8% | 20.3% | · | 26.6% | -0.78% | 23.0% | · | 17.8% | 34.3% | · | |
| EBITDA Margin | 10.8% | 11.2% | · | 10.0% | 11.1% | 11.8% | · | · | · | 11.7% | · | · | · | · | |
| ROA | -0.12% | 1.3% | · | 1.7% | 1.4% | 1.4% | · | 2.1% | 0.02% | 1.5% | · | · | · | · | |
| ROE | -0.29% | 3.0% | · | 3.8% | 3.3% | 3.2% | · | 4.7% | 0.04% | 3.2% | · | · | · | · |
Likuiditas & Solvabilitas 4
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.2 | · | 1.3 | 1.2 | 1.3 | · | 1.0 | 0.9 | 1.0 | · | · | · | · | |
| Quick Ratio | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.3 | 0.3 | · | · | · | · | |
| Debt / Equity | 0.7 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.8 | · | · | · | · | |
| LT Debt / Equity | 0.7 | 0.7 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.7 | 0.7 | · | · | · | · |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | · | · | |
| Inventory Turnover | 0.4 | 0.3 | · | 0.4 | 0.3 | 0.3 | · | 0.5 | 0.3 | 0.3 | · | · | · | · | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | 1.2 | 1.3 | · | · | · | · |
Valuasi (TTM) 4
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $60.79B | $59.47B | · | $62.72B | $59.35B | $59.58B | · | $59.35B | $54.66B | $59.86B | · | $81.87B | $94.53B | · | |
| Net Income TTM | $8.89B | $12.11B | · | $13.88B | $10.38B | $10.59B | · | $5.24B | $3.10B | $8.60B | · | $26.38B | $31.92B | · | |
| P/E | 15.6 | 12.8 | · | 9.8 | 13.3 | 13.6 | · | 31.6 | 50.9 | 18.4 | · | 7.9 | 7.3 | · | |
| Earnings Yield | 6.4% | 7.8% | · | 10.2% | 7.5% | 7.4% | · | 3.2% | 2.0% | 5.4% | · | 12.6% | 13.7% | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B |
| Laba Bersih | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B |
| EPS Dilusian | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.7 | 0.7 | 0.8 | 0.4 | 0.5 |
| Rasio Lancar | 1.2 | 1.2 | 0.9 | 1.2 | 1.4 |
| Rasio Cepat | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
- Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?
- Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?
- Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
- Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?
- This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
- Why Pfizer Could Prove to Be an Underrated GLP-1 Stock
- A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?
- Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow
- Nike Tunjuk David Denton dari Pfizer Jadi CFO Gantikan Matthew Friend; Perkirakan Manfaat Tarif di Kuartal IV
- Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 3.174 pengaju · $56.7B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 135 (-162 vs Kuartal sebelumnya) | 216 (+51 vs Kuartal sebelumnya) | 1.169 (-116 vs Kuartal sebelumnya) | 1.197 (+68 vs Kuartal sebelumnya) | +17.0M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $8.961.368.437 | 372.149.852 | 15,79% | Saham |
| STATE STREET CORP | $7.394.748.800 | 307.090.897 | 13,03% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.871.179.523 | 119.235.030 | 5,06% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $2.795.611.834 | 116.598.549 | 4,93% | Saham |
| Fisher Asset Management, LLC | $2.626.340.379 | 109.067.291 | 4,63% | Saham |
| NORGES BANK | $1.481.054.511 | 61.505.586 | 2,61% | Saham |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $845.245.059 | 35.101.539 | 1,49% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $776.142.875 | 32.231.850 | 1,37% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $770.701.325 | 32.005.869 | 1,36% | Saham |
| GOLDMAN SACHS GROUP INC | $661.178.350 | 27.457.573 | 1,17% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $655.032.155 | 27.202.332 | 1,15% | Saham |
| Capital World Investors | $535.014.038 | 22.218.190 | 0,94% | Saham |
| BlackRock, Inc. | $496.247.455 | 20.608.283 | 0,87% | Saham |
| PeakShares LLC | $470.788.000 | 19.551 | 0,83% | Saham |
| California Public Employees Retirement System | $415.668.791 | 17.261.993 | 0,73% | Saham |
| Swiss National Bank | $386.334.993 | 16.043.812 | 0,68% | Saham |
| Unisphere Establishment | $352.772.000 | 14.650.000 | 0,62% | Saham |
| National Pension Service | $349.892.971 | 14.530.439 | 0,62% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $338.582.667 | 14.060.742 | 0,60% | Saham |
| LPL Financial LLC | $335.189.276 | 13.919.821 | 0,59% | Saham |
| Sumitomo Mitsui Trust Group, Inc. | $331.724.370 | 13.775.929 | 0,58% | Saham |
| Legal & General Group Plc | $321.464.629 | 13.349.860 | 0,57% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $310.036.357 | 12.875.264 | 0,55% | Saham |
| Vanguard Global Advisers, LLC | $308.104.997 | 12.795.058 | 0,54% | Saham |
| JANE STREET GROUP, LLC | $301.895.776 | 12.537.200 | 0,53% | Opsi jual |
| BANK OF AMERICA CORP /DE/ | $288.412.018 | 11.977.243 | 0,51% | Saham |
| Robeco Institutional Asset Management B.V. | $286.990.186 | 11.918.197 | 0,51% | Saham |
| Assenagon Asset Management S.A. | $286.609.166 | 11.902.374 | 0,51% | Saham |
| VANGUARD GROUP INC | $263.690.253 | 10.589.970 | 0,46% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $257.773.294 | 10.704.871 | 0,45% | Saham |
| MORGAN STANLEY | $253.854.876 | 10.542.146 | 0,45% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $252.865.511 | 9.005.182 | 0,45% | Saham |
| NEUBERGER BERMAN GROUP LLC | $241.424.020 | 10.019.415 | 0,43% | Saham |
| AMERIPRISE FINANCIAL INC | $240.993.613 | 10.008.051 | 0,42% | Saham |
| JANE STREET GROUP, LLC | $236.270.552 | 9.811.900 | 0,42% | Opsi beli |
| ENVESTNET ASSET MANAGEMENT INC | $229.077.928 | 9.513.242 | 0,40% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $220.393.187 | 9.152.541 | 0,39% | Saham |
| HSBC HOLDINGS PLC | $210.338.535 | 8.734.989 | 0,37% | Saham |
| RHUMBLINE ADVISERS | $207.319.161 | 8.609.603 | 0,37% | Saham |
| FEDERATED HERMES, INC. | $202.552.676 | 8.411.656 | 0,36% | Saham |
| RAYMOND JAMES FINANCIAL INC | $201.533.895 | 8.369.348 | 0,36% | Saham |
| UBS Group AG | $195.120.457 | 8.103.009 | 0,34% | Saham |
| ALLIANCEBERNSTEIN L.P. | $189.845.173 | 6.760.868 | 0,33% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $186.167.224 | 7.731.197 | 0,33% | Saham |
| PRUDENTIAL FINANCIAL INC | $185.665.156 | 7.710.347 | 0,33% | Saham |
| Artemis Investment Management LLP | $183.311.336 | 7.612.597 | 0,32% | Saham |
| BARCLAYS PLC | $179.765.700 | 7.465.353 | 0,32% | Saham |
| CITADEL ADVISORS LLC | $179.051.656 | 7.435.700 | 0,32% | Opsi beli |
| Bank of New York Mellon Corp | $178.376.742 | 7.407.672 | 0,31% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $160.426.811 | 6.662.243 | 0,28% | Saham |
| Scion Asset Management, LLC | $152.880.000 | 6.000.000 | 0,27% | Opsi beli |
| SUSQUEHANNA ADVISORS GROUP, INC. | $144.480.000 | 6.000.000 | 0,25% | Saham |
| SUSQUEHANNA ADVISORS GROUP, INC. | $144.480.000 | 6.000.000 | 0,25% | Opsi jual |
| STOREBRAND ASSET MANAGEMENT AS | $124.979.920 | 5.190.196 | 0,22% | Saham |
| FRANKLIN RESOURCES INC | $123.897.114 | 5.145.229 | 0,22% | Saham |
| Ensign Peak Advisors, Inc | $123.467.238 | 5.127.377 | 0,22% | Saham |
| AVIVA PLC | $119.854.034 | 4.977.327 | 0,21% | Saham |
| CITADEL ADVISORS LLC | $119.391.313 | 4.958.111 | 0,21% | Saham |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $116.440.092 | 4.835.552 | 0,21% | Saham |
| Empower Advisory Group, LLC | $116.320.399 | 4.830.581 | 0,20% | Saham |
| D. E. Shaw & Co., Inc. | $115.981.320 | 4.816.500 | 0,20% | Opsi beli |
| JONES FINANCIAL COMPANIES LLLP | $111.805.219 | 4.602.934 | 0,20% | Saham |
| FIFTH THIRD BANCORP | $108.583.817 | 4.509.295 | 0,19% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $102.109.366 | 4.229.724 | 0,18% | Saham |
| Diamond Hill Capital Management, LLC (Investment Advisor) | $101.388.816 | 4.210.499 | 0,18% | Saham |
| Centiva Capital, LP | $100.543.632 | 4.175.400 | 0,18% | Opsi jual |
| Walleye Trading LLC | $99.982.568 | 4.152.100 | 0,18% | Opsi beli |
| LETKO, BROSSEAU & ASSOCIATES INC | $99.323.932 | 4.124.748 | 0,18% | Saham |
| MACKENZIE FINANCIAL CORP | $94.847.869 | 3.938.865 | 0,17% | Saham |
| TD Asset Management Inc | $94.564.159 | 3.927.083 | 0,17% | Saham |
| Sound Shore Management Inc /CT/ | $91.988.417 | 3.820.117 | 0,16% | Saham |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $91.535.352 | 3.801.302 | 0,16% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $90.671.275 | 3.229.034 | 0,16% | Saham |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $88.764.250 | 3.686.223 | 0,16% | Saham |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $88.487.709 | 2.657.949 | 0,16% | Saham |
| APG Asset Management N.V. | $88.030.545 | 4.179.623 | 0,16% | Saham |
| CAPTRUST FINANCIAL ADVISORS | $87.367.956 | 3.628.237 | 0,15% | Saham |
| Retirement Systems of Alabama | $83.434.503 | 3.464.888 | 0,15% | Saham |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $83.266.000 | 3.457.889 | 0,15% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $81.016.727 | 3.364.482 | 0,14% | Saham |
| Squarepoint Ops LLC | $79.704.848 | 3.310.002 | 0,14% | Saham |
| Nan Shan Life Insurance Co., Ltd. | $79.611.081 | 3.306.108 | 0,14% | Saham |
| PNC Financial Services Group, Inc. | $79.332.306 | 3.294.531 | 0,14% | Saham |
| COMMONWEALTH EQUITY SERVICES, LLC | $78.924.592 | 3.277.599 | 0,14% | Saham |
| Point72 Asset Management, L.P. | $78.291.304 | 3.251.300 | 0,14% | Opsi beli |
| MILLENNIUM MANAGEMENT LLC | $76.887.440 | 3.193.000 | 0,14% | Opsi jual |
| Cetera Investment Advisers | $76.663.659 | 3.183.708 | 0,14% | Saham |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $74.933.564 | 3.158.575 | 0,13% | Saham |
| KLP KAPITALFORVALTNING AS | $74.918.466 | 3.111.232 | 0,13% | Saham |
| D.A. DAVIDSON & CO. | $74.635.388 | 3.099.476 | 0,13% | Saham |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $73.203.200 | 3.040.000 | 0,13% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $73.106.639 | 3.035.990 | 0,13% | Saham |
| Asset Management One Co., Ltd. | $72.747.979 | 2.590.740 | 0,13% | Saham |
| MILLENNIUM MANAGEMENT LLC | $72.468.760 | 3.009.500 | 0,13% | Opsi beli |
| JANE STREET GROUP, LLC | $72.329.144 | 3.003.702 | 0,13% | Saham |
| Longaeva Partners L.P. | $71.758.400 | 2.980.000 | 0,13% | Opsi beli |
| Brandywine Global Investment Management, LLC | $71.155.361 | 2.857.645 | 0,13% | Saham |
| Vanguard Investments Australia, Ltd. | $69.990.735 | 2.906.592 | 0,12% | Saham |
| Pictet Asset Management Holding SA | $69.851.395 | 2.900.775 | 0,12% | Saham |
| BANK OF MONTREAL /CAN/ | $68.763.908 | 2.855.644 | 0,12% | Saham |
Orang dalam perusahaan 89 orang dalam · 25 pejabat · 22 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Jeffrey B Kindler | Former Chairman & CEO | 15 Des. 2010 A | 826.631 | 0 | 0 | $0 |
| Geno J Germano | Group President | 26 Feb. 2015 A | 308.254 | 0 | 0 | $0 |
| Olivier Brandicourt | Business Unit President | 31 Okt. 2013 A | 191.076 | 0 | 0 | $0 |
| David S Simmons | Business Unit President | 31 Mei 2012 A | 179.880 | 0 | 0 | $0 |
| Cavan M. Redmond | Group President | 31 Mei 2012 A | 151.138 | 0 | 0 | $0 |
| Anthony J Maddaluna | Executive Vice President | 30 Des. 2016 A | 112.087 | 0 | 0 | $0 |
| Amy Schulman | Former Exec. Vice President | 31 Des. 2013 A | 223.497 | 0 | 0 | $0 |
| Kristin C Peck | Executive Vice President | 31 Okt. 2012 A | 43.400 | 0 | 0 | $0 |
| Natale S Ricciardi | Senior Vice President | 31 Maret 2011 A | 394.778 | 0 | 0 | $0 |
| Mary S Mcleod | Former Sr. Vice President | 15 Des. 2010 A | 120.833 | 0 | 0 | $0 |
| Martin Mackay | Senior Vice President | 14 Mei 2010 A | 375.044 | 0 | 0 | $0 |
| William R Ringo | Senior Vice President | 31 Maret 2010 A | 252.798 | 0 | 0 | $0 |
| Corey S Goodman | Senior Vice President | 30 April 2009 A | 82.232 | 0 | 0 | $0 |
| Joseph M Feczko | Senior Vice President | 13 Maret 2009 A | 428.855 | 0 | 0 | $0 |
| Richard H Bagger | Senior Vice President | 31 Des. 2008 A | 54.877 | 0 | 0 | $0 |
| Allen P Waxman | Senior Vice President | 28 Feb. 2008 F | 62.341 | 0 | 0 | $0 |
| David L Shedlarz | Vice Chairman | 31 Des. 2007 A | 609.310 | 0 | 0 | $0 |
| John L Lamattina | Senior Vice President | 15 Okt. 2007 A | 383.190 | 0 | 0 | $0 |
| Alan G Levin | Senior Vice President | 14 Sep. 2007 A | 340.061 | 0 | 0 | $0 |
| Sylvia M Montero | Senior Vice President | 29 Des. 2006 A | — | 0 | 0 | $0 |
| Karen L Katen | Vice Chairman | 15 Agu 2006 A | 941.284 | 0 | 0 | $0 |
| Peter B Corr | Senior Vice President | 24 Feb. 2005 A | 148.866 | 0 | 0 | $0 |
| Charles L Hardwick | Senior Vice President | 24 Feb. 2005 A | 70.094 | 0 | 0 | $0 |
| Yvonne R Jackson | Senior VP - Human Resources | 24 Feb. 2005 F | 13.507 | 0 | 0 | $0 |
| John W Mitchell | Senior Vice President | 31 Des. 2004 I | 746.148 | 0 | 0 | $0 |
| Joseph Echevarria | Direktur | 26 Juni 2026 A | — | 0 | 0 | $0 |
| James C Smith | Direktur | 26 Juni 2026 A | 1.542 | 0 | 0 | $0 |
| James Quincey | Direktur | 26 Juni 2026 A | — | 0 | 0 | $0 |
| Cyrus Taraporevala | Direktur | 26 Juni 2026 A | — | 0 | 0 | $0 |
| Shantanu Narayen | Direktur | 26 Juni 2026 A | — | 0 | 0 | $0 |
| Marc Tessier-Lavigne | Direktur | 23 April 2015 A | — | 0 | 0 | $0 |
| George A Lorch | Direktur | 24 April 2014 A | 24.126 | 0 | 0 | $0 |
| Constance J Horner | Direktur | 24 April 2014 A | — | 0 | 0 | $0 |
| Anthony M Burns | Direktur | 25 April 2013 A | 23.989 | 0 | 0 | $0 |
| Iii William H Gray | Direktur | 25 April 2013 A | 26 | 0 | 0 | $0 |
| John P Mascotte | Direktur | 26 April 2012 A | 3.940 | 0 | 0 | $0 |
| Michael S Brown | Direktur | 28 April 2011 A | — | 0 | 0 | $0 |
| William C Steere JR | Direktur | 1 April 2011 A | 1.265.131 | 0 | 0 | $0 |
| BURT ROBERT N | Direktur | 22 April 2010 A | 12.200 | 0 | 0 | $0 |
| Dana G Mead | Direktur | 1 April 2010 A | 9.350 | 0 | 0 | $0 |
| William R Howell | Direktur | 24 April 2008 A | — | 0 | 0 | $0 |
| Henry A Mckinnell | Direktur | 28 Feb. 2007 A | 2.134.851 | 0 | 0 | $0 |
| Ruth J Simmons | Direktur | 27 April 2006 A | 1.200 | 0 | 0 | $0 |
| Stanley Ikenberry | Direktur | 27 April 2006 A | — | 0 | 0 | $0 |
| Jean Paul Valles | Direktur | 28 April 2005 A | 641.854 | 0 | 0 | $0 |
| Franklin D Raines | Direktur | 1 April 2005 A | — | 0 | 0 | $0 |
| Albert Bourla | — | 14 Agu 2026 A | 429.173 | 1 | 0 | $1.000.920 |
| Mortimer J Buckley | — | 5 Agu 2026 P | 37.632 | 1 | 0 | $960.369 |
| Jennifer B. Damico | — | 5 Agu 2026 S | 28.611 | 0 | 2 | $-134.661 |
| Ronald E Blaylock | — | 5 Agu 2026 P | 66.938 | 1 | 0 | $998.821 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 15 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Pfizer Inc. (“Pfizer”) ×9 pengajuan | 5 Agu 2024 | — | Pengajuan awal | — | SEC |
| Pfizer Inc. (“ Pfizer ”) | 6 Nov. 2020 | — | Pengajuan awal | Investasi pasif | SEC |
| Pfizer Inc. IRS Identification Nos. of above persons (entities only), Pfizer Holdings Europe IRS Identification Nos. of above persons (entities only) ×2 pengajuan | 17 Maret 2016 | — | Pengajuan awal | — | SEC |
| IRS Identification Nos. of above persons (entities only) Pfizer Inc., IRS Identification Nos. of above persons (entities only) Pfizer Holdings Europe | 1 Mei 2015 | — | Pengajuan awal | Investasi pasif | SEC |
| Pfizer Inc., Eclipse Acquisition Corp. ×11 pengajuan | 3 Nov. 2011 | — | Pengajuan awal | M&A / penjualan | SEC |
| Orang pelapor yang tidak diungkapkan | 11 April 2008 | — | Pengajuan awal | M&A / penjualan | SEC |
| G. D. Searle LLC, IRS Identification Nos. of above persons (entities only) Pfizer Inc. | 11 Sep. 2007 | — | Pengajuan awal | — | SEC |
| Pfizer Inc.;, Pfizer Holdings Europe (no IRS Identification No.) ×3 pengajuan | 14 Feb. 2006 | — | Pengajuan awal | — | SEC |
| Pfizer Overseas Pharmaceuticals, Pfizer, Inc. ; ×5 pengajuan | 14 Feb. 2006 | — | Pengajuan awal | — | SEC |
| Pfizer Overseas Pharmaceuticals (formerly named Pfizer Ireland Pharmaceuticals), Pfizer, Inc. ; ×2 pengajuan | 14 Feb. 2006 | — | Pengajuan awal | — | SEC |
| G.D. Searle LLC;, Pfizer, Inc. ; | 2 Feb. 2005 | — | Pengajuan awal | — | SEC |
| Pfizer Ireland Pharmaceuticals, Pfizer Inc.; | 13 Feb. 2004 | — | Pengajuan awal | — | SEC |
| Warner-Lambert Company LLC;, Pfizer Inc. | 17 Sep. 2003 | — | Pengajuan awal | — | SEC |
| Pfizer Holdings Europe, Pfizer Inc. | 24 Maret 2003 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 16 Maret 2001 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 247 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| FDL · First Trust Exchange-Traded Fund | 5,91% | 17.883.531 NS | 30 Juni 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 4,78% | 896.127 SH | 21 Agu 2026 | Harian |
| HDV · iShares Trust | 4,58% | 25.292.275 SH | 21 Agu 2026 | Harian |
| IHE · iShares Trust | 4,29% | 2.658.338 SH | 21 Agu 2026 | Harian |
| WBIY · Absolute Shares Trust | 4,17% | 102.076 NS | 30 Juni 2026 | N-PORT |
| SPHD · Invesco Exchange-Traded Fund Trust … | 3,33% | 4.081.344 SH | 21 Agu 2026 | Harian |
| FTXH · First Trust Exchange-Traded Fund VI | 2,97% | 44.652 NS | 30 Juni 2026 | N-PORT |
| DIVY · Tidal Trust I | 2,94% | 31.966 NS | 31 Mei 2026 | N-PORT |
| PAYR · Federated Hermes ETF Trust | 2,87% | 39.265 NS | 30 April 2026 | N-PORT |
| FLAG · Global X Funds | 2,79% | 1.720 NS | 30 April 2026 | N-PORT |
| PEY · Invesco Exchange-Traded Fund Trust | 2,59% | 1.077.623 SH | 21 Agu 2026 | Harian |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2,57% | 531.910 NS | 31 Mei 2026 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2,56% | 476.616 NS | 31 Mei 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 2,45% | 2.621.047 NS | 30 April 2026 | N-PORT |
| IYH · iShares Trust | 2,44% | 3.396.575 SH | 21 Agu 2026 | Harian |
| FDV · Federated Hermes ETF Trust | 2,44% | 685.950 NS | 30 April 2026 | N-PORT |
| ESN · Northern Lights Fund Trust II | 2,31% | 246.313 NS | 31 Mei 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 2,23% | 236.419 NS | 30 April 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 2,19% | 113.370 NS | 30 April 2026 | N-PORT |
| DVY · iShares Trust | 2,19% | 18.784.240 SH | 21 Agu 2026 | Harian |
| RXL · ProShares Trust | 2,15% | 59.288 NS | 31 Mei 2026 | N-PORT |
| GMOV · GMO ETF Trust | 2,10% | 72.971 NS | 31 Mei 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 2,02% | 17.099.868 SH | 19 Agu 2026 | Harian |
| BMVP · Invesco Exchange-Traded Fund Trust | 1,99% | 74.466 SH | 21 Agu 2026 | Harian |
| COWZ · Pacer Funds Trust | 1,99% | 13.556.580 NS | 30 April 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1,99% | 34.832 NS | 30 April 2026 | N-PORT |
| STNC · Hennessy Funds Trust | 1,99% | 68.144 NS | 30 April 2026 | N-PORT |
| DIV · Global X Funds | 1,93% | 543.656 NS | 30 April 2026 | N-PORT |
| IXJ · iShares Trust | 1,92% | 2.998.095 SH | 21 Agu 2026 | Harian |
| LYLD · Cambria ETF Trust | 1,89% | 4.263 NS | 30 April 2026 | N-PORT |
| SPDV · ETF Series Solutions | 1,88% | 63.267 NS | 30 April 2026 | N-PORT |
| SDOG · ALPS ETF Trust | 1,86% | 982.177 NS | 31 Mei 2026 | N-PORT |
| QDIV · Global X Funds | 1,82% | 22.731 NS | 31 Mei 2026 | N-PORT |
| GCOW · Pacer Funds Trust | 1,80% | 2.254.280 NS | 30 April 2026 | N-PORT |
| VLUE · iShares Trust | 1,69% | 5.931.659 SH | 21 Agu 2026 | Harian |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,65% | 539.103 NS | 30 April 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,59% | 463.448 SH | 21 Agu 2026 | Harian |
| LQAI · Exchange Listed Funds Trust | 1,53% | 1.207 NS | 30 April 2026 | N-PORT |
| ITAN · EA Series Trust | 1,39% | 47.397 NS | 29 Mei 2026 | N-PORT |
| KNGZ · First Trust Exchange-Traded Fund VI | 1,32% | 34.093 NS | 30 Juni 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,31% | 6.321 NS | 30 April 2026 | N-PORT |
| DIVB · iShares Trust | 1,29% | 888.989 SH | 21 Agu 2026 | Harian |
| GDIV · Harbor ETF Trust | 1,19% | 100.865 NS | 30 April 2026 | N-PORT |
| DIVD · EA Series Trust | 1,18% | 7.705 NS | 30 April 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 1,17% | 2.377.193 NS | 30 April 2026 | N-PORT |
| BRCE · MFS Active Exchange Traded Funds Tr… | 1,15% | 14.666 NS | 31 Mei 2026 | N-PORT |
| QDF · FlexShares Trust | 1,10% | 879.120 NS | 30 April 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 1,09% | 70.829 NS | 30 April 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 1,09% | 29.159 NS | 30 April 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 1,07% | 242.900 NS | 30 April 2026 | N-PORT |